
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
National Library of Medicine
American Academy of Child & Adolescent Psychiatry
American Academy of Pediatrics
American Society for Adolescent Psychiatry




